| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. | Chief Financial Officer | Common Stock | 26.5K | $210K | $7.92 | Nov 14, 2024 | Direct |
| Acrivon Therapeutics, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 90.1K | Mar 1, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics, Inc. | Nov 14, 2024 | 1 | -$2.91K | 4 | Nov 18, 2024 | Chief Financial Officer |
| ACRV | Acrivon Therapeutics, Inc. | Aug 14, 2024 | 1 | -$2.58K | 4 | Aug 16, 2024 | Chief Financial Officer |
| ACRV | Acrivon Therapeutics, Inc. | May 14, 2024 | 1 | -$3.08K | 4 | May 16, 2024 | Chief Financial Officer |
| ACRV | Acrivon Therapeutics, Inc. | Mar 1, 2024 | 1 | $0 | 4 | Nov 27, 2024 | Chief Financial Officer |
| ACRV | Acrivon Therapeutics, Inc. | Feb 14, 2024 | 1 | -$1.48K | 4 | Feb 16, 2024 | Chief Financial Officer |
| ACRV | Acrivon Therapeutics, Inc. | Nov 14, 2023 | 1 | -$7.47K | 4 | Nov 16, 2023 | Chief Financial Officer |
| ACRV | Acrivon Therapeutics, Inc. | Jun 16, 2023 | 2 | $34.5K | 4 | Jun 20, 2023 | Chief Financial Officer |
| ACRV | Acrivon Therapeutics, Inc. | Nov 14, 2022 | 2 | $0 | 4 | Nov 16, 2022 | Chief Financial Officer |
| ACRV | Acrivon Therapeutics, Inc. | Nov 9, 2022 | 0 | $0 | 3 | Nov 9, 2022 | Chief Financial Officer |